HOME >> BIOLOGY >> NEWS
Antibiotic inhibits cancer gene activity

A little-known antibiotic shows early promise as an anti-cancer agent, inhibiting a gene found at higher-than-normal levels in most human tumors, according to researchers at the University of Illinois at Chicago College of Medicine.

Their findings appear in the Oct. 1 issue of Cancer Research.

"We chose to target a gene believed to be over-expressed in cancer cells to screen for promising anti-cancer agents," said Andrei Gartel, assistant professor of medicine and of microbiology and immunology at UIC and principal investigator on the study.

The FoxM1 gene is responsible for turning on genes needed for cell proliferation and turning off genes that block proliferation. Uncontrolled proliferation is characteristic of cancer cells.

The researchers developed a new screening system, based on a naturally fluorescent protein called luciferase, to identify small molecules that inhibit proteins that turn genes on and off. Using this system, they identified an antibiotic, siomycin A, that specifically targets FoxM1 without affecting other cell functions.

In further experiments in tissue cultures, the researchers found that siomycin A induced cancer cells, but not normal cells, to commit suicide in a process called apoptosis.

The new screening technique, Gartel said, gives researchers a rapid way to find agents that target oncogenes -- genes believed to cause cancer. He said siomycin A, the first compound found with the method, "is particularly promising because we know that it is not toxic."

Siomycin A must now be tested against other cell lines in the laboratory and in preliminary animal experiments before human trials could be planned. Only a tiny fraction of promising candidate drugs enter clinical trials, and few of those are ever approved.

Gartel said the participation of the late Robert Costa, professor of biochemistry and molecular genetics at UIC and a leader in research on FoxM1, was c
'"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
1-Oct-2006


Page: 1 2

Related biology news :

1. Antibiotic stress, genetic response and altered permeability of E. coli
2. Antibiotic treats lymphoma of the eye
3. Antibiotic resistance markers in GM plants not a risk to human health
4. Antibiotics may not be enough to stop recurrent gastric lymphoma caused by Helicobacter pylori
5. Antibiotics help combat dangerous tropical disease
6. Antibiotic resistant bacterium uses Sonar-like strategy to see enemies or prey
7. Antibiotic-resistant bacteria increased after clindamycin use for common vaginal infection
8. Antibiotic identified as potential anti-cancer candidate
9. AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers
10. Gene therapy inhibits epilepsy in animals
11. Unusual three-drug combo inhibits growth of aggressive tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: